Related references
Note: Only part of the references are listed.A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Y-J Bang et al.
EUROPEAN JOURNAL OF CANCER (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture
Takashi Tatara et al.
ANTICANCER RESEARCH (2018)
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Sibylle Loibl et al.
EUROPEAN JOURNAL OF CANCER (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Filip Janku
CANCER TREATMENT REVIEWS (2017)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini et al.
BREAST CANCER RESEARCH (2017)
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use
George Mihai Nitulescu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl et al.
ANNALS OF ONCOLOGY (2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Enigma of Rapamycin Dosage
Suman Mukhopadhyay et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
Turgut Dogruluk et al.
CANCER RESEARCH (2015)
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Ian J. Majewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Filip Janku et al.
CELL REPORTS (2014)
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone
Binghe Xu et al.
BREAST CANCER RESEARCH (2014)
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+breast cancer cells
Brent N. Rexer et al.
BREAST CANCER RESEARCH (2014)
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Kamal S. Saini et al.
CANCER TREATMENT REVIEWS (2013)
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
Sherene Loi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Celina Garcia-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Anindita Chakrabarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt
Kui Lin et al.
SCIENCE SIGNALING (2012)
High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
Paige Yellen et al.
CELL CYCLE (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
Carlos A. Castaneda et al.
CANCER AND METASTASIS REVIEWS (2010)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
Dongwei Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
Chien-Hsing Lu et al.
CLINICAL CANCER RESEARCH (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
Suleiman Massarweh et al.
CANCER RESEARCH (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Share Paper
